Generated by AI
Abivax SA Sponsored ADR is a biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to help stabilize the immune response in chronic inflammatory diseases. The company’s lead program centers on obefazimod, a clinical-stage candidate being studied for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. Abivax SA Sponsored ADR operates as a sponsored American Depositary Receipt representing the company’s ordinary shares, giving U.S. investors access to a France-based biopharmaceutical developer. Its current work is centered on clinical research, drug development, and advancing treatments aimed at complex immune-mediated conditions. Based in Paris, Abivax SA remains positioned within the global biotechnology market as a specialist in immunology-focused therapies and late-stage clinical development.
Website7-11 Boulevard Haussmann
Paris, 75009
France
The latest articles about ABVX.
Arquitos returned 64.8% net in Q2 2026 driven by strong performance in Liquidia and Abivax. Read the full letter for more details.
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Summary of Jun 30's posts. Generated by AI.
Summary of Oct 19's posts. Generated by AI.
Investors talking about ABVX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.